Navigation Links
Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
Date:1/15/2008

classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a registration program called TIME. Tanespimycin is also being studied in a Phase 2 trial in HER2-positive metastatic breast cancer in combination with trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), is being evaluated in a Phase 1 trial in solid tumors in combination with trastuzumab and paclitaxel (Taxol(R)) and in a Phase 2 trial as monotherapy in HER2-positive metastatic breast cancer (intravenous) and in a Phase 1 trial in solid tumors (oral).

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors.

Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 safety trial, with plans to pursue development in gastroesophageal reflux disease (GERD).

For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements regarding the further development and potential safety, efficacy, regulatory status, commercialization and other c
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
2. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
3. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
4. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
5. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
6. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
7. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
8. Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
9. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
10. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
11. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/zkkg9q/blood_processing ) has announced ... - Global Strategic Business Report" report to their offering. ... US, Canada , Japan ... , Latin America , and Rest of ... 2014 through 2020. Also, a seven-year historic analysis is provided ...
(Date:6/2/2015)... 02, 2015 Research and Markets ( http://www.researchandmarkets.com/research/sn8mlw/picture_archiving ) ... Communication Systems (PACS) - Global Strategic Business Report" report ... analytics for the US, Canada , ... Asia-Pacific , Latin America , ... are provided for the period 2014 through 2020. Also, a ...
(Date:6/2/2015)... , June 2, 2015 Today the ... over 150 major food companies, retailers, and human ... Forum on Antibiotic Stewardship. CSTE is committed to ... bacteria, detect resistant strains, preserve the efficacy of ... resistant infections. CSTE continues to serve ...
Breaking Medicine Technology:Blood Processing Supplies and Equipment Market - Global Strategic Business Report 2015-2020 2Blood Processing Supplies and Equipment Market - Global Strategic Business Report 2015-2020 3Picture Archiving and Communication Systems (PACS) - Global Strategic Business Report 2015: User Demand Favors Integrated RIS/PACS Solutions 2
... 2011 Results from a two-year retrospective cohort study ... Academy of Neurology (AAN), Hawaii, U.S., showed that patients ... including hypertension, cardiac dysrhythmias and chronic ischemic heart diseases ... controls without RLS. "These findings suggest ...
... Pharmaceuticals, Inc. (AMEX: AEN ), a developer ... announced today top-line results from its clinical study evaluating ... disease (AD) and mild cognitive impairment (MCI). The clinical ... and decreasing serum free copper. In addition, secondary outcomes ...
Cached Medicine Technology:New Research Links Restless Legs Syndrome (RLS) to Cardiovascular Disease 2New Research Links Restless Legs Syndrome (RLS) to Cardiovascular Disease 3Adeona's Clinical Study of reaZin™ Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper 2Adeona's Clinical Study of reaZin™ Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper 3Adeona's Clinical Study of reaZin™ Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper 4Adeona's Clinical Study of reaZin™ Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper 5Adeona's Clinical Study of reaZin™ Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper 6Adeona's Clinical Study of reaZin™ Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper 7
(Date:6/2/2015)... 02, 2015 On Wednesday, May 27, 2015, ... to a top speed of 207.9 mph. In the ... to break the 200 mph mark. Jay Leno was ... upcoming episode of Jay Leno’s Garage, which will air on ... the 8.5 mile high speed oval at the Continental Tire ...
(Date:6/2/2015)... UCLA Health and Exer have completed negotiations ... expand urgent care services in Los Angeles County. ... of California Board of Regents and the Exer Board ... to purchase a minority share of four existing Exer ... and Northridge and creates opportunity to grow and develop ...
(Date:6/2/2015)... Prussia, PA (PRWEB) June 02, 2015 ... Outsourcing solutions for health plans in the Medicare Advantage, ... participation as a sponsor and exhibitor at AHIP’s Institute ... America’s Health Insurance Plans. The conference will be held ... exhibition booth, #1303, will offer opportunities for attendees to ...
(Date:6/2/2015)... June 02, 2015 On October 1, ... efforts for another delay. , On Monday, June ... Subcommittee for the House Ways and Means Committee, and ... Centers for Medicare and Medicaid Services, urging the administration ... CMS rolls out ICD-10. ICD-10 is the newest coding ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 IMPAK ... sorbent systems, has announced the availability of “child-resistant” ... of poisons by children, especially curious toddlers. The ... standards and tested to CFR 1700.20 protocols. The ... Cullen. , Looks Like Candy, “With the proliferation ...
Breaking Medicine News(10 mins):Health News:774 HP Hennessey Mustang Tested to 207.9 mph 2Health News:UCLA Health Partners With Exer - More Than Urgent Care 2Health News:TMG Health to Sponsor and Exhibit at AHIP’s Institute 2015 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 3Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 4Health News:IMPAK Introduces Child Resistant Zip Pouches & Bags 2
... MINNEAPOLIS, Dec. 18 MinuteClinic medical clinics in select ... now offering H1N1 vaccinations on demand seven days a ... be obtained at MinuteClinic locations in Maryland in Baltimore ... in North Carolina in Charlotte, Greensboro, Winston-Salem and Raleigh-Durham; ...
... people who have received solid organ transplants and veterinarians should ... That,s just one of the key pieces of advice from ... in the American Journal of Transplantation . ... by members of the American Society of Transplantation,s Infectious Diseases ...
... understanding of TAK1 could lead to new treatments for ... News) -- A protein switch called TAK1 helps prevent ... a team of scientists from the United States and ... improve understanding about the development of liver disease and ...
... , ... Operations to offer enhanced capabilities , ... Milford, NH and Marlboro, MA (PRWEB) December 18, 2009 -- Degree ... electronics and telecommunications industries, announced today that it has sold its IQS Testing business ...
... ... connect with clients and prospective clients, , ... Glendale, CA (Lexis Nexis) December 18, 2009 -- Milton & DeKruif, a Glendale ... it has kicked off an aggressive new client development campaign in order to raise its ...
... ... and create applications on all of their software and hardware platforms -- both new ... ... Systems announced a detailed 2010 product roadmap for NXTware Remote, its Eclipse-based cross-platform ...
Cached Medicine News:Health News:CVS MinuteClinic Now Providing H1N1 Vaccinations On Demand at all Locations in Maryland, North Carolina and Tennessee 2Health News:CVS MinuteClinic Now Providing H1N1 Vaccinations On Demand at all Locations in Maryland, North Carolina and Tennessee 3Health News:Transplant guide highlights daily infection risks from factors like pets and food 2Health News:Transplant guide highlights daily infection risks from factors like pets and food 3Health News:IQS Testing Purchased by The Compliance Management Group 2Health News:IQS Testing Purchased by The Compliance Management Group 3Health News:Milton & DeKruif Launches New Client Development Campaign 2Health News:eCube Announces 2010 NXTware Remote Product Roadmap 2Health News:eCube Announces 2010 NXTware Remote Product Roadmap 3Health News:eCube Announces 2010 NXTware Remote Product Roadmap 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: